Pharming Group N.V.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Fabrice Chouraqui
- Full Time Employees
- 404
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Darwinweg 24 Leiden Netherlands 2333 CR
- IPO Date
- Dec 23, 2020
- CIK
- 0001828316
- Website
- pharming.com
- Similar Companies
- Business
- Pharming Group N.V. (Euronext Amsterdam: PHARM; Nasdaq: PHAR) is a global biopharmaceutical company that develops, manufactures and commercializes innovative protein replacement therapies and precision medicines, including recombinant biologics and small molecules, for patients with rare, debilitating and life-threatening diseases such as hereditary angioedema, primary immunodeficiencies and mitochondrial disorders; its lead marketed products include RUCONEST (conestat alfa), a recombinant C1 esterase inhibitor approved by the FDA, EMA and MHRA for treatment of acute attacks in adult and adolescent patients with hereditary angioedema, and JOENJA (leniolisib), an oral small molecule PI3Kδ inhibitor approved by the FDA and MHRA for activated phosphoinositide 3-kinase delta syndrome. The company advances a pipeline encompassing leniolisib for expanded indications in primary immunodeficiencies with immune dysregulation, including common variable immunodeficiency and genetically identifiable conditions like ALPS-FAS and PTEN deficiency in ongoing Phase II trials, and KL1333, a small molecule for genetically confirmed primary mitochondrial diseases in a pivotal FALCON study that achieved positive interim analysis. Founded in 1988 and headquartered in Leiden, the Netherlands, with U.S. operations in Warren, New Jersey, Pharming serves patients in over 30 markets across North America, Europe, the Middle East, Africa and Asia-Pacific through subsidiaries like Pharming Technologies B.V. Recent developments include the full acquisition of Abliva AB in 2025, increasing ownership to 100% via a compulsory procedure following a tender offer, alongside a 15% reduction in general and administrative expenses announced in May 2025 to optimize capital allocation, revenue guidance increases driven by JOENJA progress, and strategic focus on immunology, hematology and pipeline expansion leveraging its transgenic platform.
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group Q1 Earnings Call Highlights
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Declines By 15.5%
Earth Science Tech (OTCMKTS:ETST) vs. Pharming Group (NASDAQ:PHAR) Head-To-Head Survey
Pharming Group announces the 2026 Annual General Meeting of Shareholders
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
Pharming Group: Crossing From Speculation To Profitability